Acute Toxicity and Outcomes of Radiation Alone Versus Concurrent Chemoradiation for Locoregional Advanced Stage Cervical Cancer by Gunawan, Rudy
Research Article
Acute Toxicity and Outcomes of Radiation Alone
Versus Concurrent Chemoradiation for
Locoregional Advanced Stage Cervical Cancer
Efek Toksisitas dan Respons terhadap Terapi Radiasi dibandingkan dengan
Kemoradiasi Konkuren pada Kanker Serviks Lokoregional Stadium Lanjut
Rudy Gunawan1, Laila Nuranna1, Nana Supriana2, Bambang Sutrisna3, Kartiwa H. Nuryanto1
1Division of Oncology Gynecology
Department of Obstetrics and Gynecology
2Department of Radiotherapy
3Department of Epidemiologic
Faculty of Medicine University of Indonesia/
Dr. Cipto Mangunkusumo Hospital
Jakarta
Abstract
Objective: To evaluate and determine the toxicity and outcomes in
patient receiving radiation (RT) alone versus concurrent chemora-
diation (CRT) using cisplatin for locoregional advanced cervical can-
cer in Dr. Cipto Mangunkusumo Hospital (RSCM).
Methods: Simple randomized single-blind clinical study, done dur-
ing the period of November 2010-April 2011, in 32 patients with lo-
coregional advanced cervical cancer (16 were treated RT alone and
the rest is treated with CRT). Teletherapy was administrated using
60Co Gamma Rays 1.3 MV and photon beam linear accelerator 4-10
MV. The radiation was administered as much as 2.0 Gy per fraction
daily for 5 days/week, for the total of 25 fractions. Brachytherapy
was performed using HDR after-loading method, with Microselec-
tron plane radiation source 129I, as much as 3x7 Gy doses to point A.
CRT using cisplatin 30 mg/m2 were given for 5 series during the ra-
diotherapy course. The toxicity assessments were carried out each
week, up until 3 months after the therapy was deemed completed
based on the RTOG and ECOG criteria.
 Results: We acquired 100% complete response in both the CRT and
RT groups. In the CRT group, we found acute gastrointestinal toxicity
grade 3 (18.75%) and grade 2 (43.75%); acute genitourinary toxic-
ity grade 3 (25%), grade 2 (31.25%); and acute hematological toxic-
ity grade 3 (12.50%) and grade 2 (25%). It is contrasted with the RT
group, in which we did not found any cases of acute gastrointestinal
toxicity, genitourinary or acute hematologic toxicity. The overall
time treatment (OTT) of 56-58 days in CRT and RT group were 25%
vs. 81.25% respectively, and the OTT of 59-70 days in CRT and RT
group were 75% vs. 18.75%, respectively.
Conclusion:The response to CRT and RT for locoregional advanced
cervical cancer was not different in 3 month evaluation. Acute gas-
trointestinal, genitourinary, and hematologic toxicities found in CRT
were higher than in RT (p=0.000; p=0.000; p=0.002).
[Indones J Obstet Gynecol 2012; 36-1:37-42]
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Abstrak
Tujuan: Untuk mengevaluasi dan mengetahui efek toksisitas dan res-
pons terhadap terapi radiasi saja dibandingkan dengan kemoradiasi
menggunakan cisplatin konkuren pada kanker serviks stadium lanjut
lokoregional di Rumah Sakit Dr. Cipto Mangunkusumo.
Metode: Penelitian dilakukan dengan metode simpel randomized sin-
gle blind, dengan sampel sejumlah 32 pasien kanker serviks stadium
lanjut lokoregional (IIB-IIIB) yang memenuhi kriteria penerimaan,
dari kurun waktu November 2010-April 2011. Sampel terbagi atas 2
kelompok terapi, 16 pasien masuk ke dalam kelompok terapi radiasi
saja dan 16 pasien masuk ke dalam kelompok terapi kemoradiasi
menggunakan cisplatin 30 mg/m2. Tele terapi dilakukan dengan sinar
gamma 60Co 1,3 MV dan sinar foton akselerator linear 4 -10 megavolt.
Radiasi diberikan bertahap sebanyak 2,0 Gy setiap hari 5 kali seming-
gu, dan diberikan sebanyak 25 kali. Brakiterapi dilakukan dengan me-
tode after-loading HDR dengan pesawat Mikroselectron sumber ra-
diasi 129I, dengan dosis 3x7 Gy di titik A. Penilaian toksisitas dilakukan
tiap minggu sampai 3 bulan setelah terapi dinyatakan lengkap berda-
sarkan kriteria RTOG dan ECOG.
Hasil: Diperoleh respons yang komplit sebesar 100% pada kelompok
kemoradiasi dan radiasi. Pada kelompok yang mendapat kemoradiasi,
didapatkan toksisitas akut gastrointestinal grade 3 (18,75%) dan
grade 2 (43,75%); toksisitas genito urinaria grade 3 (25%) dan grade
2 (31,25%); serta toksisitas akut hematologi grade 3 (12,50%) dan
grade 2 (25%), sementara kelompok yang mendapat terapi radiasi
saja tidak ditemukan satupun kasus yang mengalami toksisitas gas-
trointestinal, genito urinaria maupun hematologi. Overall time treat-
ment (OTT) 56-58 hari dicapai dalam kelompok terapi radiasi dan
kemoradiasi sebesar 25% vs 81,25%, dan OTT 59-70 hari dicapai oleh
kelomopok terapi radiasi dan kemoradiasi sebesar 75% vs 18,75%.
Kesimpulan: Respons terhadap terapi kemoradiasi dibandingkan de-
ngan terapi radiasi saja pada kanker serviks stadium lanjut lokoregional
tidak menunjukkan perbedaan yang signifikan pada evaluasi 3 bulan
paskaterapi. Toksisitas akut gastrointestinal kemoradiasi lebih tinggi
dibanding radiasi (p=0,000). Toksisitas akut genito urinaria kemoradiasi
lebih tinggi dibanding radiasi saja (p=0,000). Toksisitas akut Hematologi
kemoradiasi lebih tinggi dibanding radiasi (p=0,002). OTT kemoradiasi le-
bih panjang dibandingkan radiasi (p=0,001).
[Maj Obstet Ginekol Indones 2012; 35-1:37-42]
Kata kunci: kanker serviks lokoregional stadium lanjut , kemoradiasi
konkuren, respons terapi, toksisitas akut
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INTRODUCTION
Cervical cancer is the third most common cancer
in women, and the seventh among all cancer , with
an estimated 530,000 new cases every year and is
responsible for 275,000 deaths in 2008. More than
85% of the global burden occurs in developing
countries, where it accounts for 13% of all death.
Overall, the mortality rate is 52% and about 88%
of it occurs in developing countries. The incidence
in Indonesia is about 13,762 cases and it caused
approximately 7,493 deaths per year.1 According
to the Ministry of Health of the Republic Indonesia
in 2005, the incidence of cancer is estimated to be
in the range of 100 cases per 100,000 population
or 200,000 cases annually, and more than 70% of
cases came to the hospital in the advanced stage.2
Indonesia Association of Pathologists in 2006 re-
ported that cervical cancer was the first among 10
most frequent women cancer in Indonesia, ap-
proximately 2,459 cases3 and the mortality rate is
very high because most patients present with ad-
vanced or terminal stages.2 During 2005-2010 in
Dr. Cipto Mangunkusumo Hospital (RSCM), we ob-
tained 2,297 cases of cervical cancer, and 66.4%
arrived in advanced stages (more than stage IIB).
Thus, the outcomes of treatment are often disap-
pointing.4
A Meta-analysis study of 4,850 patients (19
studies) found that receiving chemoradiation ther-
apy increased progression-free survival and overall
survival significantly, compared with radiation
therapy alone. CRT with cisplatin regiment reduced
the number of local metastases and distant metas-
tases.5 However, other studies showed that the
outcomes of CRT in cervical cancer were still not
very satisfying, numerous studies had shown it in-
creases only 3-6% of 5-years survival rates, but the
incidence of hematologic, genitourinary and gas-
trointestinal toxicity increased significantly in CRT
groups compared with RT only groups.6
Controversy of CRT still exists, concerning
whether CRT is really feasible and effective for pa-
tients in developing countries in Asia,7 including
Indonesia, for several reasons. As regard to rea-
sons: in Phase III studies in North America and
Europe, most patients have their disease status ex-
amined by computed tomography (CT) or Magnetic
Resonance Imaging (MRI), but only a limited num-
ber of patients can undergo those examination in
Asia, including Indonesia, because of the socioeco-
nomic diversity problems. In studies in the United
Sates, para-aortic lymph nodes were evaluated
with extra peritoneal lymphadenectomy or bipedal
lymphangiography and patients who are found
positive for para-aortic lymph nodes were ex-
cluded from the studies.6,7 These examination is
not commonly used in Indonesia. Some other rea-
son is the differences which might exist in suppor-
tive care for CRT between the developed and de-
veloping countries. In the phase III studies in the
US in the 1990s, all patients are treated with low
dose rate (LDR) intracavitary brachytherapy
(ICBRT).7,8 But recently, HDR ICBRT has been per-
formed worldwide, including in Indonesia. The
combination of HDR ICBRT and CRT has been used
clinically, but only few reports regarding the out-
come of therapy have been published.9-11 There-
fore, the efficacy of CRT using HDR ICBRT has not
been thoroughly evaluated in the clinical setting.
Pearsy et al reported a National Cancer Institute
of Canada (NCIC)-sponsored trial, in which they
compare cisplatin-based CRT versus radiation
therapy alone inpatients with locally advanced cer-
vical cancer. The result has not shown any signifi-
cant different outcomes of CRT vs. RT alone in lo-
cally advanced cervical cancer, both in the survival
of 3 years (69% vs. 66%) and 5 years (62% vs.
58%), whereas the toxicity of the chemoradiation
increased 10% compared to radiation alone.12 Si-
milarly, a studying India by Negi et al, has show no
significant difference between CRT and RT, in the
evaluation complete response (60% vs. 50%), par-
tial response (20% vs. 23.1%), progressive tumors
(8% vs. 15.4%), relapse tumors (12% vs 15.4%)13
for 3 years. Therefore, the effectiveness of CRT
combined with HDR ICBRT should be evaluated
carefully, especially in Indonesia, where we have
different standards procedure and socioeconomic
diversity problems. We expected that this study
can find the outcome and toxicity effects of CRT
and RT alone in patients with locoregional ad-
vanced stage cervical cancer, improve the quality
of care and evaluate the treatment for locoregional
advanced stage cervical cancer in the RSCM.
METHODS
This study was a Randomized Clinical Trial (RCT),
with single blind method. Subjects were patients
with advanced stage locoregional cervical cancer
(IIB, IIIA, IIIB) who came to the outpatient gyne-
cology oncology clinic in RSCM, and met the criteria
inclusion during the period of November 2010 to
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April 2011. Sample size is based on statistical study
problem, with α = 5% and β = 95%, we obtained
32 patients for our sample population. Inclusion
criterias were patients newly diagnosed with cer-
vical cancer, who have been conducted to his-
topathological examination and staging according
to FIGO stage IIB-IIIB, with performance status
score ≤ 2 based on the criteria of the Eastern Co-
operative Oncology Group (ECOG) , have a normal
peripheral blood examination result (Hb ≥ 10 g%,
leucocyte count ≥ 5,000/mm3, platelets ≥ 150,000/
mm3), liver function (SGOT < 27 U/l, ALT < 36 U/l)
and kidney function (U < 50 mg/dl, creatinine 0.6-
1.20 mg/dl, CCT 68-110 ml/min), willing to partici-
pate in the study and undergoing RT or CCRT in
the RSCM. Tumor mass measurement is done by
3D ultrasound (Accuvix® xQ, Medison, Seoul, Ko-
rea), and the tumor diameter was measured in
three dimensions: the lateral width (W), dorsoven-
tral thickness (T), and craniocaudal length (L).14
External beam radiation therapy was administered
using cobalt 60 teletherapy machine. A dose of 50
Gy in 25 fractions in 5 weeks was given at the rate
of 2 Gy per fraction daily, for 5 days in a week.
Intra cavitary brachytherapy was performed using
microselectron remote controlled HDR system, Ir
based, giving a dose of 21 Gy (7 Gy per weeks in
3 weeks) to point A.15 Chemotherapy with cisplatin
30 mg/m2 is given intravenously once a week, 6-8
hours prior to radiation, on the first day of the
week for 5 series. Assessment for the response to
therapy was done 3 months after the therapy is
deemed completed (according RECIST criteria) by
measuring the degree of tumor regression with
transrectal ultrasonography, clinical examination
and cytology examination. Assessment of gastroin-
testinal toxicities and genitourinarius is based on
Radiation Therapy Oncology Group (RTOG) crite-
rias, whereas hematologic toxicities criteria is based
on a combination of Eastern Cooperative Oncology
Group (ECOG) and the Gynecologic Oncology Group
(GOG) criteria. Both effects were evaluated every
week. The toxicities which arising were treated ac-
cording to the standard management in the Divi-
sion of Gynecology Oncology and Department of
Radiotherapy RSCM. All data were analyzed statis-
tically with STATA program version 10 (Stata Cor-
poration LP, Texas, USA). This study had been granted
permission and agreement from The Committee of
The Medical Research Ethics of The Faculty of
Medicine, University of Indonesia, with certificate
ethical clearance No: 532/PT02.FK/ETIK/2010.
RESULTS
Between November 2010-April 2011, 32 eligible
patients were enrolled for this study. They were di-
vided into 2 groups: 16 were assigned to RT and
16 to CRT. The characteristics of demogrhapy, clini-
cal examination, and histopathology of subjects are
listed in Table 1, and Table 2, respectively. With re-
gard to chemotherapy, 6 cases (37.50%) received 3
cycles, 5 cases (31.25%) received 4 and 5 cycles.
Meanwhile, the other 4 patients failed to receive a
full 5 cycles caused by genitourinary toxicity
(63.7%) and gastrointestinal toxicity (36.3%).










35 - 47 years  5(31.2)  7(43.8)
48 - 68 years 11(68.8)  9(56.2)
Education 0.711
 ≤ 6 years  2(75)  10(62.5)
7 - 9 years  3(18.8)  5(31.3)
10 - 12 years  1(6.2)  1(6.2) 
Parity 0.710
1 - 3  6(37.5)  5(31.2)
4 - 9 10(62.5) 11(68.8)
Age at the fisrt sexual contact 0.288
13 - 16 years  6(37.5)  9(56.2)
17 - 22 years 10(62.5)  7(43.8)









II B  8(50)   8(50)  
III A  1(6.2) –
III B  7(43.8)  8(50)  
Tumor Size 1.000
≤ 40 mm  2(12.5)  2(12.5)
> 40 mm 14(87.5) 14(87.5)
Lymph nodes 0.669
Positive  4(25)   3(18.8)
Negative 12(75)  13(81.2)
ECOG Score 1.000
0 15(93.8) 15(93.8)
1  1(6.2)  1(16.2)
OTT 0.001
56 - 58 days 13(81.3)  4(25)  
59 - 70 days  3(18.7) 12(75)  
Cells Type 0.365
Adenocarcinoma  2(12.5)  4(25)  
Carcinosquamous 14(87.5) 12(75)  
Diffrentiation 0.911
Well  3(18.8)  4(25) 
Moderate 12(75)  11(68.8)
Poor  1(6.2)  1(6.2) 
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Table 3 showed the overall acute toxicities in
our study. At 3 months post-therapy, all of the
cases in RT and CRT groups showed 100% com-
plete response.






Grade  0  3(18.7) —
Grade  1 13(81.3) 6(37.5)
Grade  2 — 7(43.7)
Grade  3 — 3(18.8)
Genitourinary 0.000
Grade  0 16(100) —
Grade  1 — 7(43.8)
Grade  2 — 5(31.2)
Grade  3 — 4(25)  
Hematology 0.002
Grade  0 14(87.5) 4(25)  
Grade  1  2(12.5) 6(37.5)
Grade  2 — 4(25)  
Grade  3 — 2(12.5)
DISCUSSION
CRT is a standard therapy for locally advanced cer-
vical cancer in North America and in Europe, but
this method has not become a standardized therapy
in many Asian countries due to the differences in
the patient’s general status, diagnostic procedures
performed, techniques of radiotherapy, tolerance to
the chemotherapy and socioeconomic factors.7 In
this study, we compared the response and outcome
of CRT using cisplatin 30 mg/m2 with radiation
therapy alone.
This study has advantages and limitations. One
of the advantages is that the primary data directly
taken through anamnesis, physical examination, gy-
necological examination, ultrasound and other in-
vestigations. Each case was evaluated immediately
and all necessary data in accordance to objective
assessment of therapeutic response was recorded.
Meanwhile the limitation sare the number of sam-
ples, which is relatively small, and the fact that we
have not assess the disease free survival for 1 year,
recurrence rate, disease free survival and late tox-
icity yet. We used a total dose of 71 Gy for treat-
ment; duration of radiotherapy, dose and method
of radiation were similar among CRT and RT alone.
Several studies have suggested that total length of
treatment influences the efficacy of radiotherapy.16-
18 Lelieveld et al, showed that small doses of cisplatin
and lower serum levels produced maximal effect19.
Interactions leading to increased cell death, namely
radiosensitization of hypoxic cells and inhibiting re-
pair of sub lethal damage, require the presence of
cisplatin prior to and after radiation therapy. Con-
tinuous infusion of the drug fulfills this require-
ment. The majority of randomized trials were per-
formed by giving cisplatin few hours prior to radia-
tion therapy. In our study, we gave cisplatin 6 - 8
hours before radiotherapy.
In the evaluation on 3 months after the treat-
ment is completed, our study showed that CRT,
though tolerated well, failed to show any difference
in outcome, compared with RT alone, we found
that in all cases, we achieved 100% complete re-
sponse, both in CRT and RT groups. Similar result
was found by Kundan SC et al. After 3 months of
completion of CRT, there was no statistically sig-
nificant difference in response rates among RT and
CRT group (p=0.235), but the survival rate at the
end of 2 years were as follow: locoregional relapse-
free survival is 69% vs. 61.6%, DFS 68.3% vs.
59.4%, OS 68.3% vs. 62.3% respectively among RT
and CRT group.20 Similarly, in the study by M.
Garipa et al, tolerability and efficacy of the cisplatin
continuous infusion during radiotherapy were stud-
ied. The tumor response, survival rate and pelvic
control of 44 patients with stage IIB-IIIB cervical
carcinoma were prospectively randomized into
two groups: radiation alone versus radiation plus
cisplatin.21 Tumor responses were no different in
the end of the treatment and 3 months after the
completion of treatment. Five-year pelvic control
rates were 69.4% and 63.9% (p=0.7), survival
rates were 52.0% and 48.9% (p=0.7), and disease-
free survival rates were 67.5% and 58.7% (p=0.3)
for the RT and the CRT groups, respectively. Al-
though the continuous infusion of cisplatin during
radiotherapy was well tolerated, this additional
treatment in the form of CRT did not appear to
show any improvement in pelvic control, survival
rate, or disease-free survival rate. In our study, US
abdomen was mainly used to evaluate para-aortic
nodal status, which is an inferior modality com-
pared to lymphangiography and CT scans, and we
did not exclude patients with positive nodes. In our
set up, it is difficult to carry out extensive work up
like laparotomy, lymphangiography and CT scans
due to financial issues and those procedures are
not our routine protocol to manage advanced cer-
vical cancer. Many patients may have had para-
aortic nodes that were not detected with US abdo-
men, adding to our inferior results. Meta analysis
by Green et al suggested that the benefit of CRT is
more apparent in early stages and when disease is
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confined to the pelvis.22 Another factor contribut-
ing to our inferior results may be the small sample
size, which may not have picked the difference of
response in two treatment arms. The trial by
Pearcy et al also had the smallest number of pa-
tients among all prospective randomized trials.12
The majority of treatment failures were seen in the
pelvis in the irradiated area. An analysis on the pat-
tern of failure reveals that 29.4% of those who
failed had pelvic tumor as a component of first site
of failure. The study conducted by Negi et al did
not show any benefit of CRT when compared to RT
alone in locally advanced cervical cancer patients.13
That could be due to more bulk of tumor stage per
stage; poor nutritional status; less number of pa-
tients in both arms, not enough to pick up statisti-
cally significant small difference in outcome; the
difference of dose and scheduling of radiotherapy
or chemotherapy. Our results are also approximat-
ely similar to the results of 6 randomized multi-
institutional trial by the NCIC, which evaluate the
patient on the third month of complete response
on all group therapy. But in our study, we did not
evaluate the 3 and 5 years survival rate because
this study has not yet reached 1-year since the
completion of therapy. Other similiarity with the
NCIC study is that this study did not performa se-
lection of patients on the suspicion of metastases
in lymph nodes, but all patients, despite positive
enlargement of lymph nodes which was found with
ultrasound (4 patients in RT group and 3 patients
in CRT group), were enrolled in this study.
Acute gastrointestinal and genitourinary toxici-
ties were the principal adverse effects in our study.
The frequency of grade 2 and 3 acute gastrointes-
tinal toxicities and genitourinary toxicities was sig-
nificantly higher in the CRT arm (p=0.000). Even
though acute toxicities were found more in CRT
group, they were manageable. In the majority of the
patients, the GI toxicities manifested as vomiting
and diarrhea, which were infrequent in RT alone
group. The genitourinary toxicities manifested as
nocturia happening more than 1 hour, dysuria, pel-
vic pain and vesica urinary spasm, which were not
found in RT group. The hematology toxicity grade
2 and 3 were noted in 6 patients in CRT but were
not found in RT group. Thus, there was a significant
difference (p=0.002). Compared to the other ran-
domized trials using cisplatin, we had less hemato-
logical complications, which may be due to lesser
dose of cisplatin and 5-Fluorouracil that we used.
The other factor leading to higher hematology tox-
icity in other trials is the incorporation of hy-
droxyurea in the treatment. The most important ad-
verse effect with cisplatinum was emesis, but it was
successfully managed by one of the 5-hydroxytryp-
tamine antagonists. In our study, genitourinary tox-
icity grade 1 occurred in 7 patients (43.7%) in CRT
group. No genitourinary toxicity was noted in the
RT group. There was no patient death caused by
concurrent cytotoxic drug therapy. Grade 3-4 gas-
trointestinal toxicities were higher in patients in cis-
platin group in a trial by Whitney et al (8%) as com-
pared to HU group, and there were no grade 4
nephrotoxicity. Grade 3 and 4 of other toxicities
were encountered less than 2%.8 In a study by
Saibishkumar et al comparing patients receiving
CRT to RT, severe acute toxicities (grade 3 ≥ RTOG
criteria) were significantly higher in CRT arm (31.6
%) compared to the RT groups (11.6%), with p
value < 0.001. The occurence rate of hematologic
toxicity of grade 2 anemia, neutropenia and throm-
bocytopenia were 11.4%, 31.4% and 2.8%, respec-
tively.23 LT Tan et al showed that CRT using cis-
platin had higher toxicity than RT alone but still had
a good tolerance when given to the population of
cervical cancer carried out without selection.24 We
also tried to link the OTT with the overall acute tox-
icity occurring in patients during therapy, and there
was a significant difference between the two groups
of OTT with the acute toxicities gastrointestinal, he-
matologic and genitourinary (p=0.003; p=0.005 and
p=0.008) respectively. In this study, we found a sig-
nificant differences between the two treatment
groups against the cost of therapy with p-value =
0.000. Significant differences are due to the addition
cost of the chemotherapy drug and the incremental
cost of hospitalization because patients receiving
chemotherapy require hospitalization of at least
one day for one series. And also adding to the cost
is drugs, functioned as an anticipation of events that
will result in toxicity effects, which are given to-
gether during chemotherapy administration.
OTT is one of the prognostic factors in radio-ther-
apy for cervical cancer. Nag S et al, recommend that
the OTT should not exceed 56 days.25 Doses of ra-
diation in the others study protocols used 80 Gy to
point A with the OTT anticipated 49 to 70 days.
Some studies suggest that OTT affected the success
of radiation.18-20 This study obtained the ranges of
OTT were 56-59 days with median 56.2 days in RT
group, 58-70 days with median 63.5 days in CRT
group. It was significantly different duration OTT
with both of the arms (p=0.001).
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CONCLUSION
The outcomes of CRT group and RT group were
similar in patients with advanced locoregional cer-
vical cancer on evaluation at 3 months after com-
pletion of therapy. The incidences of acute gastro-
intestinal, genitourinary and acute hematologic
toxicities in CRT group were higher than RT alone,
with a significant difference (p=0.000, p=0.00,
p=0.002). Overall Treatment Time (OTT) in CRT
group is longer than in RT group (p=0.001). Our
study could still be improved by evaluating the pa-
tient for a longer time, in order to determine the
disease free survival (DFS), overall survival, recur-
rence rate, relapse free survival and late toxicity.
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